查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
幹細胞治療的全球市場（~2028）：按類型、細胞來源和治療應用分類
市場調查報告書
商品編碼
1397373

幹細胞治療的全球市場（~2028）：按類型、細胞來源和治療應用分類

Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 197 Pages | 訂單完成後即時交付

價格
簡介目錄

報告摘要

調查範圍
調查年份 2021-2028
基準年 2022年
預測期 2023-2028
單元 金額（美元）
部分 細胞來源/類型/治療用途/地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

全球幹細胞治療市場規模預計將從2023年的2.86億美元成長到2028年的6.15億美元，預測期內年複合成長率為16.5%。

主要參與者正在專注於開發針對各種疾病的新型幹細胞療法，這是未來幾年可能影響市場成長的主要因素之一。近年來 FDA 對幹細胞治療的核准增加以及臨床試驗數量的大幅增加預計也將推動市場成長。

從類型來看，異體幹細胞部門將在 2022 年佔據壓倒性佔有率。異體幹細胞治療允許從一種細胞來源獲得多種給藥，使其經濟可行且耗時更少。目前，全球有超過 10 種異體幹細胞治療已上市並核准。

按細胞來源分類，脂肪組織來源的 MSC部門將在 2022 年獲得壓倒性的佔有率。同時，骨髓間質幹細胞部門預計在預測期內將以顯著的年複合成長率成長。骨髓來源的 MSC 是幹細胞治療的最優選類型。骨髓間質幹細胞的易獲得性和體外加工所需的時間短是推動這些細胞的使用和促進該部門成長的關鍵因素。

按地區分類，亞太地區預計在預測期內將以顯著的年複合成長率成長。在韓國，政府對幹細胞治療的核准正在增加。此外，該地區幹細胞療法開發的行業合作夥伴關係可能會進一步加速該地區的市場成長。

本報告調查了全球幹細胞治療市場，並提供了市場概況、市場成長和市場機會的各種影響因素分析、技術和專利趨勢、管道分析、法律制度以及市場規模趨勢和預測。，編制詳細品類、區域分析、競爭形勢、主要企業概況等

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 技術分析
  • 影響客戶業務的趨勢和顛覆
  • 價值鏈分析
  • 生態系市場地圖
  • 供應鏈分析
  • 波特五力分析
  • 監管分析
  • 價格分析
  • 專利分析
  • 重大會議及活動
  • 管道分析
  • 主要利害關係人和採購標準

第6章幹細胞治療市場：依細胞來源分類

  • 脂肪組織來源的 MSC（間質幹細胞）
  • 骨髓來源的 MSC（間質幹細胞）
  • 胎盤/臍帶來源的 MSC（間質幹細胞）
  • 其他

第7章幹細胞治療市場：依類型

  • 異體幹細胞治療
  • 自體幹細胞治療

第8章幹細胞治療市場：依治療應用分類

  • 肌肉骨骼疾病
  • 傷口/手術
  • 發炎疾病/自體免疫疾病
  • 心血管疾病
  • 神經病變
  • 其他

第9章幹細胞治療市場：依地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第10章競爭形勢

  • 主要企業的招募策略
  • 收益佔有率分析
  • 市場佔有率分析
  • 企業評價矩陣
  • 主要企業的競爭基準化分析
  • 前 15 名公司的區域足跡
  • 新創企業/小型企業評估矩陣
  • 新創公司/中小企業的競爭基準化分析
  • 競爭格局及趨勢

第11章 公司簡介

  • 主要企業
    • SMITH+NEPHEW
    • MEDIPOST
    • JCR PHARMACEUTICALS CO., LTD.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • ANTEROGEN CO., LTD.
    • CORESTEM, INC.
    • PHARMICELL CO., LTD
    • NUVASIVE, INC.
    • RTI SURGICAL
    • ALLOSOURCE
    • HOLOSTEM TERAPIE AVANZATE SRL
    • ORTHOFIX MEDICAL INC.
    • STEMPEUTICS RESEARCH PVT LTD.
    • REGROW BIOSCIENCES PVT LTD.
  • 其他公司
    • ATHERSYS, INC.
    • MESOBLAST LTD.
    • BIORESTORATIVE THERAPIES, INC.
    • PLURISTEM THERAPEUTICS INC.
    • BRAINSTORM CELL LIMITED
    • GAMIDA CELL
    • VIACYTE, INC.
    • KANGSTEM BIOTECH CO., LTD.
    • HOPE BIOSCIENCES
    • CELLULAR BIOMEDICINE GROUP
    • PERSONALIZED STEM CELLS

第12章附錄

簡介目錄
Product Code: BT 5049

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Million
SegmentsCell Source, Type, Therapeutic Application and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East and Africa

The global stem cell therapy market is projected to reach USD 615 million by 2028 from USD 286 million in 2023, at a CAGR of 16.5% during the forecast period. Key market players are focusing on developing new stem cell therapies for various disease conditions this is one of the major factor is likely to impact the market growth in coming years. The increasing number of clinical trials has largely in past few years coupled with rise in FDA approvals for stem cell therapy is anticipated to give momentum to the market growth.

"The allogeneic stem cell segment accounted dominant share in 2022"

The stem cell therapy market is segmented into allogeneic and autologous. Allogeneic segment accounted for the dominant share in 2022. In allogeneic stem cell therapy, one cell source can produce numerous doses, thus making allogeneic therapy economically viable and less time-consuming, these are some of the major elements responsible for the doninat share of the segment. Presently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

"Bone Marrow-derived MSCs segment is anticipated to grow at significant CAGR"

Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. In 2022, the adipose tissue-derived MSCs segment gained dominant share in the stem cell therapy market. Bone marrow-derived mesenchymal stem cells most preferred type for are stem cell therapies. Easy availability of Bone marrow MSCs and less time required for in-vitro processing are some of the major factorslikely to give momentum to the use of bone marrow derived MSCs uplifting the segmental growth.

"Asia Pacific region is likely to grow at a faster pace."

The stem cell therapy market is segmented into North America, Europe, Asia Pacific and Rest of the world. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for stem cell therapy in South Korea. Furthermore, industrial collabrations in the region for stem cell therapy development is further likely to give pace for the market growth in the region. For instance, Reyon Pharmaceutical and Therabest entered into a joint development agreement for NK cell therapy for treating solid cancer. Under this agreement, the two companies will jointly develop iPSC (induced pluripotent stem cell)-derived NK cell therapy 'TB-100' for solid cancer indications.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Asia-Pacific -20%, Europe -30%, ROW-10%

List of Companies Profiled in the Report:

  • Smith+Nephew (UK)
  • MEDIPOST Co. Ltd. (South Korea)
  • Anterogen Co. Ltd. (South Korea)
  • CORESTEM (South Korea)
  • Pharmicell Co. Ltd. (South Korea)
  • NuVasive Inc. (US)
  • RTI Surgical (US)
  • AlloSource (US)
  • JCR Pharmaceuticals Co. Ltd. (Japan)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Holostem Terapie Avanzate Srl (Italy)
  • Orthofix (US)
  • Regrow Biosciences Pvt Ltd. (India)
  • STEMPEUTICS RESEARCH PVT LTD. (India)
  • Athersys (US)
  • Mesoblast Ltd (Australia)
  • Biorestorative Therapies Inc. (US)
  • Pluristem Inc. (Israel)
  • Brainstorm Cell Limited. (US)
  • ViaCyte Inc. (US)
  • Gamida Cell (US)
  • Kangstem Biotech (South Korea)
  • Hope Biosciences (US)
  • Cellular Biomedicine Group (US)
  • Personalized Stem Cells (US)

Research Coverage:

This report provides a detailed picture of the stem cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.
  • Product Development/Innovation: Detailed insights on newly launched products of the stem cell therapy market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the stem cell therapy market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the stem cell therapy market.
  • Pipeline Analysis: Detailed information on stem cell therapy under phase 3 clinical trials.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Smith+Nephew (UK), MEDIPOST Co. Ltd. (South Korea), Anterogen Co. Ltd. (South Korea), CORESTEM (South Korea) and among others in the stem cell therapy market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 YEARS CONSIDERED
  • 1.5 CURRENCY
  • 1.6 RESEARCH LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES
  • 1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
    • FIGURE 5 SMITH+NEPHEW: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 PRIMARY INSIGHTS
    • FIGURE 6 VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT METHODOLOGY: STEM CELL THERAPY MARKET
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    • FIGURE 8 CAGR PROJECTIONS: STEM CELL THERAPY MARKET
    • FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 STUDY ASSUMPTIONS
  • 2.5 RISK ANALYSIS
  • 2.6 IMPACT OF RECESSION ON STEM CELL THERAPY MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 STEM CELL THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 REGIONAL SNAPSHOT OF STEM CELL THERAPY MARKET

4 PREMIUM INSIGHTS

  • 4.1 STEM CELL THERAPY MARKET OVERVIEW
    • FIGURE 15 INCREASING INVESTMENTS AND FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
  • 4.2 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE AND COUNTRY, 2022
    • FIGURE 16 ALLOGENEIC STEM CELL THERAPY ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 STEM CELL THERAPY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 17 SOUTH KOREA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 STEM CELL THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increased funding for stem cell research
    • TABLE 4 FUNDING FOR STEM CELL RESEARCH BY INDIAN COUNCIL OF MEDICAL RESEARCH, 2019-2022 (USD)
    • TABLE 5 FUNDING FOR CELL-BASED RESEARCH BY NATIONAL INSTITUTES OF HEALTH, 2018-2023 (USD MILLION)
      • 5.2.1.2 Rising number of collaborations among healthcare institutes
      • 5.2.1.3 Increasing number of clinical trials for stem cell-based therapies
    • FIGURE 19 NUMBER OF CLINICAL TRIALS, 2015-2022
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Ethical concerns related to use of embryonic stem cells
      • 5.2.2.2 High cost of cell-based research and stem cell therapy
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased availability of alternatives to embryonic stem cells
      • 5.2.3.2 Growing demand for cell and gene therapies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technological limitations
  • 5.3 TECHNOLOGY ANALYSIS
    • TABLE 6 COMPARISON BETWEEN STEM CELL THERAPIES AND GENE THERAPIES
  • 5.4 DISRUPTIONS AND TRENDS IMPACTING CUSTOMER'S BUSINESS
    • FIGURE 20 REVENUE SHIFT AND NEW POCKET FOR KEY PLAYERS IN STEM CELL THERAPY MARKET
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 21 STEM CELL THERAPY MARKET: VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM MARKET MAP
    • FIGURE 22 STEM CELL THERAPY MARKET: ECOSYSTEM MARKET MAP
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 STEM CELL THERAPY MARKET: SUPPLY CHAIN ANALYSIS
    • TABLE 7 SUPPLY CHAIN ANALYSIS: ROLE OF COMMERCIAL-SCALE/KEY MANUFACTURERS
    • TABLE 8 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITION RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY LANDSCAPE
      • 5.9.1.1 North America
    • TABLE 9 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
      • 5.9.1.2 Europe
    • TABLE 10 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
      • 5.9.1.3 Asia Pacific
    • TABLE 11 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
      • 5.9.1.4 Rest of the World
    • TABLE 12 REST OF THE WORLD: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PRICING ANALYSIS
    • 5.10.1 PRICING ANALYSIS
    • TABLE 17 AVERAGE SELLING PRICE OF DRUG THERAPIES OFFERED BY KEY PLAYERS IN STEM CELL THERAPY MARKET
    • 5.10.2 AVERAGE SELLING PRICE TREND FOR STEM CELL THERAPIES
  • 5.11 PATENT ANALYSIS
    • FIGURE 24 STEM CELL THERAPY: PATENT ANALYSIS, 2013-2023
  • 5.12 KEY CONFERENCES & EVENTS
    • TABLE 18 LIST OF KEY CONFERENCES & EVENTS, 2023-2024
  • 5.13 PIPELINE ANALYSIS
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • FIGURE 25 KEY STAKEHOLDERS
    • 5.14.1 KEY BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR END USERS

6 STEM CELL THERAPY MARKET, BY CELL SOURCE

  • 6.1 INTRODUCTION
    • TABLE 19 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
  • 6.2 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
    • 6.2.1 EASE OF ISOLATION AND HARVESTING TO DRIVE GROWTH
    • TABLE 20 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 21 NORTH AMERICA: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 EUROPE: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS
    • 6.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH
    • TABLE 24 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS
    • 6.4.1 LOW CHANCES OF REJECTION FROM IMMUNE SYSTEM TO PROPEL GROWTH
    • TABLE 28 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 29 NORTH AMERICA: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 EUROPE: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 OTHER CELL SOURCES
    • TABLE 32 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)

7 STEM CELL THERAPY MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 36 STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 ALLOGENEIC STEM CELL THERAPY
    • 7.2.1 ECONOMICALLY VIABLE AND LESS TIME-CONSUMING-KEY FACTORS DRIVING MARKET GROWTH
    • TABLE 37 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 AUTOLOGOUS STEM CELL THERAPY
    • 7.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE GROWTH
    • TABLE 41 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 42 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 45 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
  • 8.2 MUSCULOSKELETAL DISORDERS
    • 8.2.1 INCREASING CASES OF OSTEOARTHRITIS TO DRIVE MARKET
    • TABLE 46 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 WOUNDS & SURGERIES
    • 8.3.1 INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH
    • TABLE 50 STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
    • 8.4.1 INCREASING CLINICAL TRIALS TO SUPPORT MARKET GROWTH
    • TABLE 54 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 55 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 CARDIOVASCULAR DISEASES
    • 8.5.1 INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH TO DRIVE MARKET
    • TABLE 58 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.6 NEUROLOGICAL DISORDERS
    • 8.6.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
    • TABLE 62 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.7 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 66 STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

9 STEM CELL THERAPY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 70 STEM CELL THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
    • TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 73 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Increase in stem cell therapy approvals to drive market
    • TABLE 75 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 76 US: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Increase in research activities targeted toward stem cell therapies to propel market
    • TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 79 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.2.3 RECESSION IMPACT ON NORTH AMERICAN STEM CELL THERAPY MARKET
  • 9.3 EUROPE
    • TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 83 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Increasing incidence of sports-related injuries to drive market
    • TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 86 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Rising adoption of cell-based therapies to propel market
    • TABLE 88 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 89 UK: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 90 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Rising R&D expenditure for stem cell therapy to support market growth
    • TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 92 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
    • TABLE 94 ITALY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 95 ITALY: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 ITALY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising prevalence of CVD to propel market
    • TABLE 97 SPAIN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 98 SPAIN: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 SPAIN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 100 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 101 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.3.7 RECESSION IMPACT ON EUROPEAN STEM CELL THERAPY MARKET
  • 9.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
    • TABLE 103 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Growing geriatric population and faster regulatory approval process to augment market growth
    • TABLE 107 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 108 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 109 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.4.2 SOUTH KOREA
      • 9.4.2.1 Presence of major players to support market growth in South Korea
    • TABLE 110 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 111 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Rising incidence of neurodegenerative disorders and diabetes to drive market
    • TABLE 113 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 114 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.4.4 CHINA
      • 9.4.4.1 Increasing investments in stem cell research to drive market
    • TABLE 116 CHINA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 117 CHINA: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 CHINA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 119 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 120 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.4.6 RECESSION IMPACT ON ASIA PACIFIC STEM CELL THERAPY MARKET
  • 9.5 REST OF THE WORLD
    • TABLE 122 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2028 (USD MILLION)
    • TABLE 123 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021-2028 (USD MILLION)
    • 9.5.1 RECESSION IMPACT ON REST OF THE WORLD STEM CELL THERAPY MARKET

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 29 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 10.3 REVENUE SHARE ANALYSIS
    • FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS, 2020-2022 (USD MILLION)
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 31 STEM CELL THERAPY MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
    • TABLE 125 STEM CELL THERAPY MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 10.5 COMPANY EVALUATION MATRIX
    • FIGURE 32 STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
  • 10.6 COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 126 THERAPEUTIC APPLICATION FOOTPRINT OF COMPANIES
  • 10.7 REGIONAL FOOTPRINT OF TOP 15 COMPANIES
    • TABLE 127 REGIONAL FOOTPRINT OF COMPANIES
  • 10.8 STARTUP/SME EVALUATION MATRIX
    • FIGURE 33 STEM CELL THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022
    • 10.8.1 PROGRESSIVE COMPANIES
    • 10.8.2 RESPONSIVE COMPANIES
    • 10.8.3 DYNAMIC COMPANIES
    • 10.8.4 STARTING BLOCKS
  • 10.9 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
    • TABLE 128 STEM CELL THERAPY MARKET: PRODUCT FOOTPRINT ANALYSIS OF STARTUPS/SMES
    • TABLE 129 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 10.10 COMPETITIVE SCENARIOS AND TRENDS
    • 10.10.1 PRODUCT APPROVALS
    • TABLE 130 STEM CELL THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020-OCTOBER 2023
    • 10.10.2 DEALS
    • TABLE 131 STEM CELL THERAPY MARKET: DEALS, JANUARY 2020-OCTOBER 2023
    • 10.10.3 OTHER DEVELOPMENTS
    • TABLE 132 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020-OCTOBER 2023

11 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 11.1 KEY PLAYERS
    • 11.1.1 SMITH+NEPHEW
    • TABLE 133 SMITH+NEPHEW: BUSINESS OVERVIEW
    • FIGURE 34 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
    • 11.1.2 MEDIPOST
    • TABLE 134 MEDIPOST: BUSINESS OVERVIEW
    • FIGURE 35 MEDIPOST: COMPANY SNAPSHOT (2021)
    • 11.1.3 JCR PHARMACEUTICALS CO., LTD.
    • TABLE 135 JCR PHARMACEUTICALS CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 36 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2022)
    • 11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • TABLE 136 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
    • FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
    • 11.1.5 ANTEROGEN CO., LTD.
    • TABLE 137 ANTEROGEN CO., LTD.: BUSINESS OVERVIEW
    • 11.1.6 CORESTEM, INC.
    • TABLE 138 CORESTEM INC.: BUSINESS OVERVIEW
    • FIGURE 38 CORESTEM INC.: COMPANY SNAPSHOT (2021)
    • 11.1.7 PHARMICELL CO., LTD
    • TABLE 139 PHARMICELL CO., LTD: BUSINESS OVERVIEW
    • 11.1.8 NUVASIVE, INC.
    • TABLE 140 NUVASIVE, INC.: BUSINESS OVERVIEW
    • FIGURE 39 NUVASIVE, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.9 RTI SURGICAL
    • TABLE 141 RTI SURGICAL: BUSINESS OVERVIEW
    • 11.1.10 ALLOSOURCE
    • TABLE 142 ALLOSOURCE: BUSINESS OVERVIEW
    • 11.1.11 HOLOSTEM TERAPIE AVANZATE SRL
    • TABLE 143 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW
    • 11.1.12 ORTHOFIX MEDICAL INC.
    • TABLE 144 ORTHOFIX MEDICAL INC.: BUSINESS OVERVIEW
    • FIGURE 40 ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT (2022)
    • 11.1.13 STEMPEUTICS RESEARCH PVT LTD.
    • TABLE 145 STEMPEUTICS RESEARCH PVT LTD.: BUSINESS OVERVIEW
    • 11.1.14 REGROW BIOSCIENCES PVT LTD.
    • TABLE 146 REGROW BIOSCIENCES PVT LTD.: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 ATHERSYS, INC.
    • TABLE 147 ATHERSYS, INC.: BUSINESS OVERVIEW
    • 11.2.2 MESOBLAST LTD.
    • TABLE 148 MESOBLAST LTD.: BUSINESS OVERVIEW
    • 11.2.3 BIORESTORATIVE THERAPIES, INC.
    • TABLE 149 BIORESTORATIVE THERAPIES, INC.: BUSINESS OVERVIEW
    • 11.2.4 PLURISTEM THERAPEUTICS INC.
    • TABLE 150 PLURISTEM THERAPEUTICS INC.: BUSINESS OVERVIEW
    • 11.2.5 BRAINSTORM CELL LIMITED
    • TABLE 151 BRAINSTORM CELL LIMITED: BUSINESS OVERVIEW
    • 11.2.6 GAMIDA CELL
    • TABLE 152 GAMIDA CELL: BUSINESS OVERVIEW
    • 11.2.7 VIACYTE, INC.
    • TABLE 153 VIACYTE, INC.: BUSINESS OVERVIEW
    • 11.2.8 KANGSTEM BIOTECH CO., LTD.
    • TABLE 154 KANGSTEM BIOTECH CO., LTD.: BUSINESS OVERVIEW
    • 11.2.9 HOPE BIOSCIENCES
    • TABLE 155 HOPE BIOSCIENCES: BUSINESS OVERVIEW
    • 11.2.10 CELLULAR BIOMEDICINE GROUP
    • TABLE 156 CELLULAR BIOMEDICINE GROUP: BUSINESS OVERVIEW
    • 11.2.11 PERSONALIZED STEM CELLS
    • TABLE 157 PERSONALIZED STEM CELLS: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS